Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 720  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Articlesmenu-bullet Search Instructions Online Submission Subscribe Etcetera Contact
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (568 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  References
 ::  Article Figures

 Article Access Statistics
    PDF Downloaded5    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


  Table of Contents     
Year : 2021  |  Volume : 67  |  Issue : 3  |  Page : 180-181

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine

1 Department of Medicine, Hospital General de Castellon, Castellon, Spain
2 Department of Ophthalmology, Hospital of Vinaros, Castellon, Spain

Date of Submission17-Mar-2021
Date of Decision24-Mar-2021
Date of Acceptance02-Jun-2021
Date of Web Publication13-Aug-2021

Correspondence Address:
M Manuel Roca
Department of Ophthalmology, Hospital of Vinaros, Castellon
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jpgm.JPGM_254_21

Rights and Permissions

How to cite this article:
Roca B, Rambla M, Roca M M. Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine. J Postgrad Med 2021;67:180-1

How to cite this URL:
Roca B, Rambla M, Roca M M. Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine. J Postgrad Med [serial online] 2021 [cited 2021 Dec 3];67:180-1. Available from:

As COVID-19 vaccines are being authorized and recommended for use worldwide, it is important to understand what is known about them, particularly in terms of effectiveness and safety.[1] Common side-effects from these vaccines include mild grade fever, fatigue, headache, myalgia, and pain at the injection site,[2] but information available about them is still limited. Herein we report a patient who presented with supraclavicular reactive lymphadenopathies after receiving the COVID-19 BNT162b2 vaccine (Pfizer-BioNTech).

A previously healthy 29-year-old woman presented with a two-day history of mild discomfort and a lump in her left supraclavicular region. Seven days earlier she had received the first dose of above mentioned COVID-19 vaccine in ipsilateral deltoid muscle. On examination she was in good health. Two lymphadenopathies, 1.5 cm and 1 cm in diameter respectively, were noted in her left supraclavicular region [Figure 1]. Mild pain on pressure was also present in the vaccine injection site.
Figure 1: Lymphadenopathies in the left supraclavicular region

Click here to view

Her routine investigations, including blood cell counts, biochemistry and serologies, was normal. Chest radiograph was normal. Ultrasound examination disclosed two left supraclavicular lymphadenopathies [Figure 2] with no other abnormalities found in the neck or axillary regions. As the patient was otherwise asymptomatic, she uneventfully received the second dose of the same COVID-19 vaccine, 21 days after the first dose. She required no specific treatment. The lymphadenopathies progressively diminished in size and finally disappeared over the next few weeks.
Figure 2: Lymphadenopathies in the left supraclavicular region

Click here to view

Lymphatic vessels from the deltoid region drain in the axillary and supraclavicular lymph nodes, and both axillary and supraclavicular lymphadenopathies have been previously described as side effect of different vaccines.[3],[4] Recently two other cases of reactive lymphadenopathies following COVID-19 vaccinations, presenting as a lump in the neck, have been reported.[5] But this a barely known side effect of COVID-19 vaccines.[2] Since a diagnosis of malignancy is considered in patients presenting with left supraclavicular lymphadenopathies, awareness of this side effect of COVID-19 vaccines is particularly important to avoid unnecessary evaluation and reduce anxiety of affected patients.[6]

Declaration of patient consent

The authors certify that appropriate patient consent was obtained.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

 :: References Top

Wu CP, Adhi F, Culver D. Vaccination for COVID-19: Is it important and what should you know about it? Clevel Clin J Med 2021 (in press).  Back to cited text no. 1
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16.  Back to cited text no. 2
Pereira MP, Flores P, Neto AS. Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination. BMJ Case Rep 2019;12:e231582.  Back to cited text no. 3
Toy H, Karasoy D, Keser M. Lymphadenitis caused by H1N1 vaccination: Case report. Vaccine 2010;28:2158-60.  Back to cited text no. 4
Mitchell OR, Dave R, Bekker J, Brennan PA. Supraclavicular lymphadenopathy following COVID-19 vaccination: An increasing presentation to the two-week wait neck lump clinic? Br J Oral Maxillofac Surg 2021;59:384-5.  Back to cited text no. 5
Lehman CD, D'Alessandro HA, Mendoza DP, Succi MD, Kambadakone A, Lamb LR. Unilateral lymphadenopathy after COVID-19 vaccination: A practical management plan for radiologists across specialties. J Am Coll Radiol 2021;18:843-52.  Back to cited text no. 6


  [Figure 1], [Figure 2]

This article has been cited by
1 COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature
Jihe Lim, Seun Ah Lee, Eun Kyung Khil, Sun-Ju Byeon, Hee Joon Kang, Jung-Ah Choi
Seminars in Oncology. 2021;
[Pubmed] | [DOI]


Print this article  Email this article
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow